Search research articles
Contact Us
Filters
Showing results (621-630 of 686) with videos related to
Page
of 69
Sort By:
CA: a Cancer Journal for Clinicians
|
July 15, 2020
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic
Manish A Shah, M Frances Emlen, Tsiporah Shore, et al.
Blood
|
January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
John C Byrd, John M Pagel, Farrukh T Awan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
John P Leonard, Morton Coleman, Jamie C Ketas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2008
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P Martin, A Chadburn, P Christos, et al.
Blood
|
December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.
Blood
|
July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
David J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Leukemia & Lymphoma
|
August 14, 2025
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents
Seda S Tolu, Caitlin Gribbin, Zhengming Chen, et al.
Blood Advances
|
January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Sven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Blood Advances
|
April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101
Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.
American Journal of Hematology
|
March 15, 2020
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403
Lawrence D Kaplan, Matthew J Maurer, Wendy Stock, et al.
Page
of 69
Search research articles
Search
Showing results (621-630 of 686) with videos related to
Sort By:
Page
of 69
CA: a Cancer Journal for Clinicians
|
July 15, 2020
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic
Manish A Shah, M Frances Emlen, Tsiporah Shore, et al.
Blood
|
January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
John C Byrd, John M Pagel, Farrukh T Awan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
John P Leonard, Morton Coleman, Jamie C Ketas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2008
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P Martin, A Chadburn, P Christos, et al.
Blood
|
December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.
Blood
|
July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
David J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Leukemia & Lymphoma
|
August 14, 2025
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents
Seda S Tolu, Caitlin Gribbin, Zhengming Chen, et al.
Blood Advances
|
January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Sven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Blood Advances
|
April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101
Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.
American Journal of Hematology
|
March 15, 2020
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403
Lawrence D Kaplan, Matthew J Maurer, Wendy Stock, et al.
Page
of 69